KN046 not checked
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
10 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “In combine therapy stage, KN046 placebo is 5 milligram per kilogram, every 3 weeks. In maintain stage, KN046 placebo is 5 milligram per kilogram, every 2 weeks.”In the company’s words, NCT04474119 on ClinicalTrials.gov
- Tested for
- Advanced Non-small Cell Lung Cancer (2 trials), Squamous Non-small-cell Lung Cancer, Advanced Pancreatic Ductal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Stage IV Non-small Cell Lung Cancer, Thymic Carcinoma, Advanced HCC, Triple-negative Breast Cancer and 2 more
- Main trialPhase 3
- “This study is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of KN046 plus paclitaxel and carboplatin versus placebo plus paclitaxel and carboplatin in subjects with advanced squamous NSCLC who have not previously received systemic treatment.”In the company’s words, NCT04474119 on ClinicalTrials.gov
Other drugs for Advanced Non-small Cell Lung Cancer
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- CobimetinibRoche · Phase 2/3
- DivarasibRoche · Phase 3
- EntrectinibRoche · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials10
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Unknown | 30 Aug 2022 | KN046 in Subjects With Advanced Squamous Non-small Cell Lung Cancer | |
| Phase 3Unknown | 30 Apr 2024 | KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma. | |
| Phase 2/3Terminated | 13 Feb 2023 | KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent | |
| Phase 2Completed | 26 Aug 2021 | KN046 in Subjects With Late Stage Esophageal Squamous Cell Carcinoma | |
| Phase 2Terminated | 30 Jul 2022 | KN046 in Patients With Advanced Non-small Cell Lung Cancer | |
| Phase 2Terminated | 7 Jul 2023 | KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma | |
| Phase 2Completed | 31 Dec 2024 | Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer | |
| Phase 1/2Terminated | 30 May 2022 | KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma | |
| Phase 1/2Completed | 16 Aug 2022 | A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer | |
| Phase 1Completed | 3 Jan 2023 | KN046 in Subjects With Advanced Solid Tumors and Lymphoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026